Transfer factor therapy in ataxia--telangiectasia.

The effects of weekly doses of transfer factor in four patients with ataxia--telangiectasia were investigated following a total course of 2 months therapy. Transfer factor administration showed no influence on the absolute lymphocyte counts, T-cell rosettes or antibody titres to EBV, but it caused conversion of skin-test reactivity and production of MIF to various antigens. There was a dissociation in blastic transformation response, the skin-test responses and MIF production. Serum interferon levels were low before, and 2, 6 and 24 hr after, therapy. Clinically no improvement in infections was observed following transfer factor therapy.
AuthorsA I Berkel, F Ersoy, L B Epstein, L E Spitler
JournalClinical and experimental immunology (Clin Exp Immunol) Vol. 29 Issue 3 Pg. 376-84 (Sep 1977) ISSN: 0009-9104 [Print] ENGLAND
PMID201409 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Viral
  • Macrophage Migration-Inhibitory Factors
  • Transfer Factor
  • Interferons
  • Antibodies, Viral (analysis)
  • Ataxia Telangiectasia (therapy)
  • Child
  • Herpesvirus 4, Human (immunology)
  • Humans
  • Interferons (analysis)
  • Leukocyte Count
  • Lymphocyte Activation
  • Macrophage Migration-Inhibitory Factors (biosynthesis)
  • Male
  • Skin Tests
  • Transfer Factor (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: